

Franziska Di Pauli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/566288/publications.pdf>

Version: 2024-02-01

68
papers

1,184
citations

394421

19
h-index

414414

32
g-index

69
all docs

69
docs citations

69
times ranked

1533
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. <i>European Journal of Neurology</i> , 2022, 29, 1538-1544.	3.3	12
2	Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate. <i>Wiener Medizinische Wochenschrift</i> , 2022, , 1.	1.1	2
3	Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis. <i>Journal of Central Nervous System Disease</i> , 2022, 14, 117957352210848.	1.9	0
4	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	3.0	16
5	Olfactory threshold predicts treatment response in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1541-1552.	3.0	3
6	Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication—a retrospective multicentre study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103810.	2.0	4
7	Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. <i>European Journal of Neurology</i> , 2022, 29, 2772-2780.	3.3	3
8	Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1871-1880.	3.0	5
9	Long-term outcome after COVID-19 infection in multiple sclerosis: A nationwide multicenter matched-control study. <i>European Journal of Neurology</i> , 2022, 29, 3050-3060.	3.3	9
10	Multiple sclerosis and COVID-19: How many are at risk?. <i>European Journal of Neurology</i> , 2021, 28, 3369-3374.	3.3	37
11	Macular ganglion cell—inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 684-694.	3.0	36
12	Cerebrospinal fluid protein in Guillain-Barré syndrome: Need for age-dependent interpretation. <i>European Journal of Neurology</i> , 2021, 28, 965-973.	3.3	12
13	Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. <i>European Journal of Neurology</i> , 2021, 28, 1609-1616.	3.3	18
14	Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2037-2045.	3.3	10
15	Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry. <i>Journal of Neurology</i> , 2021, 268, 4303-4310.	3.6	8
16	Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	26
17	Differential Binding of Autoantibodies to MOC Isoforms in Inflammatory Demyelinating Diseases. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	16
18	Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study. <i>Frontiers in Immunology</i> , 2021, 12, 675307.	4.8	12

#	ARTICLE	IF	CITATIONS
19	COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry. PLoS ONE, 2021, 16, e0255316.	2.5	27
20	Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study. Multiple Sclerosis Journal, 2021, 27, 2209-2218.	3.0	25
21	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association. Frontiers in Immunology, 2021, 12, 769653.	4.8	3
22	Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years. Scientific Reports, 2021, 11, 23317.	3.3	4
23	Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPriMS Score. Frontiers in Neurology, 2021, 12, 766956.	2.4	5
24	Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. Multiple Sclerosis Journal, 2020, 26, 57-68.	3.0	20
25	Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria. Multiple Sclerosis Journal, 2020, 26, 69-78.	3.0	51
26	Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS. Multiple Sclerosis Journal, 2020, 26, 706-715.	3.0	14
27	Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1682-1690.	3.0	25
28	To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101908.	2.0	29
29	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. PLoS ONE, 2020, 15, e0239453.	2.5	7
30	Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732094573.	1.0	2
31	Transverse myelitis as a rare presentation of antiphospholipid-antibody-associated disorders. Multiple Sclerosis and Related Disorders, 2020, 45, 102405.	2.0	0
32	Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732096634.	1.0	15
33	Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102403.	2.0	22
34	Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab: A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry. Frontiers in Neurology, 2020, 11, 676.	2.4	5
35	Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma. Frontiers in Immunology, 2020, 11, 515556.	4.8	5
36	Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. Multiple Sclerosis and Related Disorders, 2020, 43, 102155.	2.0	18

#	ARTICLE	IF	CITATIONS
37	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. PLoS ONE, 2020, 15, e0234333.	2.5	2
38	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
39	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
40	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
41	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
42	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
43	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
44	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
45	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
46	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
47	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
48	Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study. Brain and Behavior, 2019, 9, e01332.	2.2	7
49	Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988598.	1.0	6
50	Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 196-203.	3.0	67
51	Change of olfactory function as a marker of inflammatory activity and disability progression in MS. Multiple Sclerosis Journal, 2019, 25, 267-274.	3.0	29
52	New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases. Multiple Sclerosis and Related Disorders, 2018, 22, 35-37.	2.0	11
53	Smoking is not associated with higher prevalence of JC virus in MS patients. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 907-910.	2.9	2
54	Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 2435.	4.8	1

#	ARTICLE	IF	CITATIONS
55	Dream Content in Patients With Sleep Apnea: A Prospective Sleep Laboratory Study. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 41-46.	2.6	9
56	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?. <i>Frontiers in Immunology</i> , 2018, 9, 2753.	4.8	49
57	Transient impairment of olfactory threshold in acute multiple sclerosis relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 74-77.	2.0	19
58	Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1241-1248.	3.0	56
59	Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. <i>PLoS ONE</i> , 2017, 12, e0182462.	2.5	26
60	Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. <i>PLoS ONE</i> , 2017, 12, e0174005.	2.5	29
61	Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis – The PaSiMS II study. <i>PLoS ONE</i> , 2017, 12, e0181458.	2.5	2
62	Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. <i>PLoS ONE</i> , 2016, 11, e0158978.	2.5	56
63	Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 150-154.	2.0	11
64	Fulminant demyelinating encephalomyelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e175.	6.0	75
65	Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. <i>Journal of Neuroimmunology</i> , 2015, 287, 98-105.	2.3	8
66	Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: Case report and review of the literature. <i>Journal of Clinical Virology</i> , 2014, 60, 424-427.	3.1	10
67	Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. <i>Clinical Immunology</i> , 2011, 138, 247-254.	3.2	180
68	Features of intrathecal immunoglobulins in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2010, 288, 147-150.	0.6	23